Department of Diabetes, Monash University, Central Clinical School, 99 Commercial Road, Melbourne, Australia; Department of Biochemistry, Monash University, Melbourne, Australia.
Department of Diabetes, Monash University, Central Clinical School, 99 Commercial Road, Melbourne, Australia; Drug Discovery Biology, Monash Institute of Pharmaceutical Science, Monash University Parkville Campus, 381 Royal Parade, Parkville, 3052 VIC, Australia.
Cell Metab. 2023 Feb 7;35(2):253-273. doi: 10.1016/j.cmet.2023.01.004.
Recent clinical trials in people with type 2 diabetes have demonstrated beneficial actions on heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are consistent with improved glucose control and significant weight loss. But GLP-1RAs may also have additive benefits by improving postprandial dysmetabolism. In diabetes, dysregulated postprandial nutrient excursions trigger inflammation, oxidative stress, endothelial dysfunction, thrombogenicity, and endotoxemia; alter hormone levels; and modulate cardiac output and regional blood and lymphatic flow. In this perspective, we explore the actions of GLP-1RAs on the postprandial state and their potential role in end-organ benefits observed in recent trials.
最近针对 2 型糖尿病患者的临床试验表明，GLP-1RA 治疗可带来心脏和肾脏结局的改善。在某种程度上，这些作用与改善血糖控制和显著减重有关。但 GLP-1RA 可能还通过改善餐后代谢紊乱而具有额外获益。在糖尿病中，餐后营养物质波动失调会引发炎症、氧化应激、内皮功能障碍、血栓形成和内毒素血症；改变激素水平；并调节心输出量和局部血液及淋巴液流动。在本观点中，我们探讨了 GLP-1RA 对餐后状态的作用及其在近期试验中观察到的终末器官获益中的潜在作用。
Zotero 插件